口服抗糖尿病药物的特点及合理应用附视频

被引：10

作者：

胡翠宁

高峰

机构：

[1] 华中科技大学同济医学院附属协和医院内分泌科

来源：

医药导报 | 2009年 / 11期

关键词：

抗糖尿病药物; 糖尿病,2型;

D O I：

暂无

中图分类号：

R977.1 [激素类药物];

学科分类号：

1007 ;

摘要：

随着生活方式和生活环境的改变,糖尿病已成为严重威胁人类健康的慢性、进行性、终身性疾病。早期良好控制血糖有助于防止各种并发症的发生。迄今为止,口服抗糖尿病药物仍是治疗2型糖尿病的重要手段,该文就现在应用于临床以及即将应用于临床的各种口服抗糖尿病药物进行综述。

引用

页码：1393 / 1398

页数：6

共 11 条

[1] Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling [J].

Calvert, John W. ;

Gundewar, Susheel ;

Jha, Saurabh ;

Greer, James J. M. ;

Bestermann, William H. ;

Tian, Rong ;

Lefer, David J. .

DIABETES, 2008, 57 (03) :696-705

[2]

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes[J] . Gary A. Herman,Arthur Bergman,Catherine Stevens,Paul Kotey,Bingming Yi,Peng Zhao,Bruno Dietrich,George Golor,Andreas Schrodter,Bart Keymeulen,Kenneth C. Lasseter,Mark S. Kipnes,Karen Snyder,Deborah Hilliard,Michael Tanen,Caroline Cilissen,Marina De Smet,Inge de Lepeleire,Kristien Van Dyck,Amy Q. Wang,Wei Z

[3]

ABCC8 and ABCC9: ABC transporters that regulate K + channels[J] . Pflügers Archiv - European Journal of Physiology . 2007 (5)

[4]

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes[J] . A Mari,W M. Sallas,Y L. He,C Watson,M Ligueros-Saylan,B E. Dunning,C F. Deacon,J J. Holst,J E. Foley.The Journal of Clinical Endocrinology ＆ Metabolism . 2005 (8)

[5]

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial[J] . Jean-Louis Chiasson,Robert G Josse,Ramon Gomis,Markolf Hanefeld,Avraham Karasik,Markku Laakso.The Lancet . 2002 (9323)

[6] Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide [J].

Holstein, A ;

Plaschke, A ;

Egberts, EH .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (06) :467-473

[7] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [J].

Turner, RC ;

Holman, RR ;

Stratton, IM ;

Cull, CA ;

Matthews, DR ;

Manley, SE ;

Frighi, V ;

Wright, D ;

Neil, A ;

Kohner, E ;

McElroy, H ;

Fox, C ;

Hadden, D .

LANCET, 1998, 352 (9131) :854-865

[8] Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL [J].

Desfaits, AC ;

Serri, O ;

Renier, G .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (10) :1150-1156

[9]

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. LL Lipscombe,T Gomes,LE Levesque. The Journal of The American Medical Association . 2007

[10]

Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action. Renstrom E,Barg S,Thevenod F,et al. Diabetes Research and Clinical Practice .

← 1 2 →